U nas zapłacisz kartą
Brymonidyna na twarz - Tajemnicze Piękno Naturalnej Pielęgnacji
How should I use brimonidine ophthalmic?
Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.
Wash your hands before using the eye drops.
Use only the number of drops your doctor has prescribed.
Do not touch the tip of the eye dropper or place it directly on your eye. A contaminated dropper can infect your eye, which could lead to serious vision problems.
Wait at least 5 minutes before using any other eye drops your doctor has prescribed.
Do not use the eye drops if the liquid looks cloudy, has changed colors, or has particles in it. Call your pharmacist for new medicine.
Store at room temperature away from moisture and heat. Do not freeze. Keep the bottle tightly closed when not in use.
brimonidine ophthalmic
Brimonidine ophthalmic (for the eyes) is used to reduce pressure inside the eyes in people with open-angle glaucoma or ocular hypertension. The Alphagan P brand of this medicine is available only with a prescription.
The Lumify brand of brimonidine ophthalmic is available without a prescription, and is used to relieve eye redness and irritation.
Alphagan P is for use in adults and children as young as 2 years old. Lumify is for use in adults and children who are at least 5 years old.
Brimonidine ophthalmic may also be used for purposes not listed in this medication guide.
What should I discuss with my healthcare provider before using brimonidine ophthalmic?
Associated Data
The data presented in this study are available in article and Supplementary Materials.
Brimonidine, a selective alpha-2 adrenergic agonist used for the treatment of open-angle glaucoma, has been shown to cause neurological side effects such as unresponsiveness, lethargy, hypoventilation, and stupor, mimicking opioid toxicity. We report one case of transient encephalopathy in a toddler, in whom accidental brimonidine toxicity was suspected and then confirmed by a toxicology study. The healthy 8-month-old girl was taken to the pediatric ER since she was drowsy and hypotonic with miosis. The computed tomography scan of her brain and toxicological workup of her blood and urine were negative. Starting from the fourth hour, the child progressively improved, and by the sixth hour, she recovered to a normal state of consciousness. A survey of available drugs within the child’s reach showed the presence of brimonidine. Thus, ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) was applied to quantify the brimonidine in urine and plasma samples, showing levels of 8.40 ng/mL and 0.79 ng/mL, respectively. To our knowledge, this is the first report to determine brimonidine levels in urine and plasma using UPLC-MS/MS. Insufficient knowledge on the part of family members about the potential hazards of an apparently innocuous, topical medication such as eye drops may put children at a greater risk of poisoning. Necessary warnings should be given to parents with greater care when prescribing this medication.
Keywords: brimonidine, eye drop poisoning, tandem mass spectrometry